Although effective, Gefitinib, Erlotinib, and the other EGFR TKIs are beneficial to only a small population of patients as only about 15% of Caucasian and 50% of Asian lung adenocarcinoma patients harbor EGFR mutations (14, 15). Here, EGFR is linked to lung adenocarcinoma.